The Medical Advisor

Researchers delving into the timing of subsequent colonoscopies found that for some people, the risks are no different if they wait 15 years instead of 10. The invasive and expensive nature of colonoscopies makes determining how to maximize their usefulness—particularly when it comes to follow-up screenings—a prominent topic of research. It’s undisputed that the surgical-based test can save lives, but the timing remains a moving target. Three years ago, the U.S. Preventive Services Task Force lowered the recommended age for the first colorectal cancer screening by five years—from 50 years of age to 45. Now, the gap between the first and second tests is being scrutinized. Long-term data used in a JAMA Oncology study published May 2, 2024 suggests it may be time to move the follow-up screening back five years in certain circumstances. Specifically, the study indicates that anyone who doesn’t have a family history of colorectal cancer and whose first colonoscopy was free of polyps—abnorm...

Medically Reviewed by: OneDayMD Editorial Team Last Updated: May 2026 Abstract Background: Repurposed antiparasitic agents, including ivermectin and benzimidazoles (fenbendazole and mebendazole), have gained attention for their potential anticancer properties, particularly in colorectal cancer. Preclinical studies suggest these agents may exert antitumor effects through mechanisms such as inhibition of cell proliferation and disruption of key oncogenic pathways, including Wnt/β-catenin signaling. Objective: To summarize and evaluate a compilation of case reports describing the use of ivermectin and benzimidazole-based regimens in patients with colorectal cancer, with a focus on advanced-stage disease. Methods: This review analyzes a curated series of 80+ case reports involving patients with colorectal or related gastrointestinal cancers treated with ivermectin in combination with fenbendazole or mebendazole, often alongside standard therapies such as chemotherapy. Reported outco...